Skip to main content
Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · Real-Time Price · USD
1.440
+0.010 (0.70%)
Feb 21, 2025, 4:00 PM EST - Market closed

SONN Revenue

Sonnet BioTherapeutics Holdings had revenue of $1.00M in the quarter ending December 31, 2024, with 5,268.84% growth. This brings the company's revenue in the last twelve months to $1.00M, up 674.14% year-over-year. In the fiscal year ending September 30, 2024, Sonnet BioTherapeutics Holdings had annual revenue of $18.63K, down -87.40%.

Revenue (ttm)
$1.00M
Revenue Growth
+674.14%
P/S Ratio
1.50
Revenue / Employee
$76,923
Employees
13
Market Cap
4.41M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Sep 30, 202418.63K-129.18K-87.40%
Sep 30, 2023147.81K-202.14K-57.76%
Sep 30, 2022349.94K-133.68K-27.64%
Sep 30, 2021483.63K--
Sep 30, 2020---
Sep 30, 2019 Pro Pro Pro
Sep 30, 2018 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 400.28B
Johnson & Johnson 88.82B
Merck & Co. 64.17B
AbbVie 56.33B
AstraZeneca 54.07B
Novartis AG 51.72B
Eli Lilly and Company 45.04B
Thermo Fisher Scientific 42.88B
Revenue Rankings

SONN News

More News